Six of these reported cases were detected in outpatient settings among individuals with no known CRE risk factors like overnight hospital stays, dialysis treatment, surgery within the past year or invasive device exposure within the previous two days.
The CRE detected in the 10 Colorado patients contained the New Delhi metallo-β-lactamase enzyme, which makes the bacteria resistant to a broad range of antibiotics. This particular strain of CRE is uncommon in the U.S. and considered to be a global threat.
“The finding that 6 of 10 recent NDM-producing CRE are community-associated suggests that the epidemiology of CRE could be changing. Further surveillance is required to determine whether this pattern continues,” wrote the study’s authors.
More articles on infection control:
Arkansas mumps outbreak continues, cases hit 2,200
Top 10 infection control stories, Dec. 12-16
National Park Service looks to expand infectious disease surveillance
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
